Avani to Represent Dermatology Products Featuring Invisicare(R)
LAS VEGAS, Dec. 6 /PRNewswire-FirstCall/ -- Skinvisible, Inc. (OTC Bulletin Board: SKVI) / (Website: http://www.skinvisible.com), is pleased to announce that it has signed a marketing agreement with Avani International for India. This follows Skinvisible's recent announcement that it was granted a comprehensive patent in India for Skinvisible's proprietary polymer delivery system, Invisicare. Invisicare enhances the delivery of topical dermatology products on the skin.
The agreement with Avani is part of Skinvisible's continued strategy to quickly expand its reach around the globe. Avani will seek licenses in India for topical products Skinvisible has developed for the treatment of acne, fungal infections, atopic dermatitis and hand sanitizers. They will also facilitate clinical studies and manufacturing in India.
"It is important for Skinvisible to develop partnerships with companies such as Avani as they have established relationships with pharmaceutical and consumer goods companies in India. This helps us fast track our marketing efforts in the country and generate license fees and royalties quicker than marketing in India ourselves," said Mr. Terry Howlett, President and CEO of Skinvisible Inc.
"India and its expanding population of over 1 billion people offers tremendous market opportunities for Skinvisible and its Invisicare technology and products," said Ash Chawla, Chairman & CEO of Avani. "This agreement allows us to introduce Invisicare to Indian pharmaceutical manufacturers that we know need this technology."
Skinvisible has patented its technology and trademarked its polymer delivery system Invisicare(R). Invisicare is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time. They are non-occlusive and allow normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants. See: http://www.Invisicare.com
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare(R) to pharmaceutical and cosmeceutical companies as well as assisting companies in revitalizing or enhancing their existing skin care products. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. See: http://www.skinvisible.com
About Avani International
Avani International is a leading business development firm, with services ranging from product commercialization to launch, marketing, sales, and distribution for pharmaceutical, biotechnology and medical device industries. Avani enjoys strong relationships with manufacturers in India and has pioneered relations and business growth between US and Indian companies for the past five years. See: http://www.avaniinternational.com
This press release contains 'forward looking' statements within the
meaning of Section 21A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, and are
subject to the safe harbors created thereby. Such statements involve
certain risks and uncertainties associated with an emerging company. Actual
results could differ materially from those projected in the forward looking
statements as a result of risk factors discussed in Skinvisible, Inc.
reports on file with the U.S. Securities and Exchange Commission
(including, but not limited to, a report on Form 10Q for the quarter ending
September 30, 2007)
Terry Howlett, President/CEO
Skinvisible Pharmaceuticals, Inc.
|SOURCE Skinvisible, Inc.|
Copyright©2007 PR Newswire.
All rights reserved